Quarterly Activities/Appendix 4C Cash Flow Report
Filed with ASX ·
6ix is reading this filing.
Earlier from LTR Pharma
- Australian-Developed ED Nasal Spray Now Being Prescribed in the U.S.
- First ROXUS Prescriptions Fulfilled in the United States
- SPONTAN Phase II Final Results
- FY26 Results Announcement
- SPONTAN Real-World Study Reports 93% Response
Follow LTR Pharma into a list and get an email when it puts out news.
Follow LTR Pharma